{"nctId":"NCT00710866","briefTitle":"Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity","startDateStruct":{"date":"2008-08"},"conditions":["Influenza"],"count":262,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)"]}],"interventions":[{"name":"Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)","otherNames":["VAXIGRIPÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Child healthy (stable chronic conditions acceptable) as established by health assessment interview and verbal history-directed health examination\n* Child between and including 6 months of age and 23 months of age (up to and including the day before 24 months of age)\n* Child is available and can complete all relevant procedures during the entire study period\n* Parent or legal guardian is available and can be reached by phone during the entire study period\n* Parent/guardian provides written informed consent\n* Parent/guardian is fluent in English\n\nExclusion Criteria:\n\n* Child has history of laboratory-confirmed influenza\n* Child has history of any prior influenza immunization\n* Child has history of anaphylactic reaction to any component of the vaccine (i.e. egg)\n* Child has received immune globulin or other blood products within the prior six weeks\n* Child has received injected or oral steroids within the prior six weeks (inhaled or topical steroids allowed)\n* Child has a bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection (thrombocytopenia, coagulation disorder, anti-coagulant therapy)\n* Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical device during the study period\n* Child is scheduled to receive a live vaccine (notably measles, mumps, rubella or varicella vaccines) during the study period\n* Child has a health condition which, in the opinion of the investigator, would interfere with the evaluation or pose a health risk to the child","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1)","description":"Seroprotection rate: HI titers =\\>40","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/59/07(H1N1)","description":"Seroprotection rate: HI titers =\\>40","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate Infants(6-11 Months)-A/Brisbane/10/07(H3N2)","description":"Seroprotection rate: HI titers =\\>40","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate Toddlers(12-23 Months)-A/Brisbane/10/07(H3N2)","description":"Seroprotection rate: HI titers =\\>40","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate Infants (6-11 Months)-B/Florida/4/06(Yamagata)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate Toddlers (12-23 Months)-B/Florida/4/06(Yamagata)","description":"Seroprotection rate: HI titers =\\>40","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events: Fever After Either Dose - Infants 6-11 Months","description":"Fever defined as temperature \\>= 38 C","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events: Fever After Either Dose - Toddlers(12-23 Months)-","description":"Fever defined as temperature \\>= 38 C","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":["Irritability","Sleep disturbance","Decreased appetite","Drowsiness","Tenderness"]}}}